ē Greg Duncan, Executive Vice President, President of North American Operations
ē Jean-Christophe Tellier, MD, Executive Vice President, President of European Operations
Vers la version en franÁaisNaar de nederlandstalige versie
BRUSSELS, 25 May 07:00 (CET) - regulated information - With UCB set to enter its growth phase in 2012 and building on major advances in its late-stage pipeline, UCB announced today that two new members will join the companyís Executive Committee as of July 1, 2011.
The two new members are the heads of the US and European commercial operations, respectively Greg Duncan, currently Senior Vice President and President of UCBís North American Operations, and Jean-Christophe Tellier, joining UCB from Ipsen.
These additions will allow Mark McDade, UCBís EVP Global Operations and Chief Operating Officer to focus on UCBís future growth markets outside the US and Europe, while driving UCBís commercial growth strategy across all geographies. Mark will also continue to lead Business Development and maintains his global leadership of the companyís Marketing, Access and Medical Affairs functions, preparing the launch and commercialization of the next generation of medicines from UCBís promising late-stage pipeline, such as brivaracetam in epilepsy, epratuzumab in Lupus and Sclerostin antibody in post-menopausal osteoporosis and fracture healing.
|Greg Duncan joined UCB in 2007 to lead UCBís European Operations. He then became President of European and Emerging Market Operations until 2009 when he was appointed President of UCBís North American operations. Greg has a degree in Economics from the State University of New York, Albany, and a MBA in Marketing and Management from the Emory University in Atlanta. He started his career in 1989, within Pfizer, where he had spent 17 years holding various managerial positions. His last position within Pfizer was as President Latin America.|
|Jean-Christophe Tellier is joining UCB from Ipsen where he was President & General Manager Ipsen US. His role at Ipsen was to strengthen Ipsenís specialty care business in North America, in the areas of endocrinology and neurology. Prior to joining Ipsen in May 2009, he was Executive Vice President and Chief Commercial Officer at MacroGenics Inc, a Maryland-based biotechnology company. Jean-Christophe Tellier spent the largest part of his career at Novartis (Ciba) where he held several commercial operations roles in France, Belgium and Switzerland. Jean-Christophe Tellier is a physician specialized in rheumatology (University of Paris V, France). |
Detailed biographies of the members of the Executive Committee can be found on UCBís website
For further Information:
Antje Witte, Investor Relations, UCB
Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, Michael.email@example.com@ucb.com
UCB, Brussels, Belgium () is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9000 people in over 40 countries, UCB produced revenue of EUR 3.22 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.www.ucb.com